Trastuzumab: No negative impact on cardiac function

(NRG Oncology) Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news